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Abstract
Background: Minocycline and a non-steroidal anti-inflammatory drug (NSAID) indomethacin, have anti-
inflammatory activities and are both used in the management of rheumatoid arthritis. However, there are no
reports on whether coadministration of these drugs could potentiate each other’s activities in alleviating pain and
weight bearing deficits during arthritis.
Methods: LPS was injected to BALB/c mice intraperitoneally (i.p.) to induce thermal hyperalgesia. The hot plate test
was used to study thermal nociception in naïve BALB/c and C57BL/6 mice and BALB/c mice with LPS-induced
thermal hyperalgesia and to evaluate antinociceptive effects of drugs administered i.p. Monoarthritis was induced
by injection of LPS intra-articularly into the right hind (RH) limb ankle joint of C57BL/6 mice. Weight bearing
changes and the effect of i.p. drug administration were analyzed in freely moving mice using the video-based
CatWalk gait analysis system.
Results: In naïve mice indomethacin (5 to 50 mg/kg) had no significant activity, minocycline (25 to 100 mg/kg)
produced hyperalgesia to thermal nociception, however, coadministration of minocycline 50 mg/kg with
indomethacin 5 or 10 mg/kg produced significant antinociceptive effects in the hot plate test. A selective inhibitor
of COX-1, FR122047 (10 mg/kg) and a selective COX-2 inhibitor, CAY10404 (10 mg/kg) had no significant
antinociceptive activities to thermal nociception in naïve mice, however, coadministration of minocycline, with
CAY10404 but not FR122047 produced significant antinociceptive effects. In mice with LPS-induced hyperalgesia
vehicle, indomethacin (10 mg/kg) or minocycline (50 mg/kg) did not produce significant changes, however,
coadministration of minocycline plus indomethacin resulted in antinociceptive activity. LPS-induced RH limb
monoarthritis resulted in weight bearing (RH/left hind (LH) limb paw pressure ratios) and RH/LH print area ratios
deficits. Treatment with indomethacin (1 mg/kg) or minocycline (50 mg/kg) had no effects on the weight bearing
and print area ratios deficits of monoarthritic mice. However, combination of minocycline plus indomethacin
restored weight bearing and paw print area ratios of monoarthritic mice similar to that observed in non-arthritic
control mice.
Conclusions: Coadministration of indomethacin or a selective COX-2 inhibitor, CAY10404 with minocycline
potentiates their effects and results in antinociception against thermal nociception, reduction of thermal
hyperalgesia and alleviation of weight bearing deficits in monoarthritic mice at doses where either drug alone
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reproduction in any medium, provided the original work is properly cited.has no significant activity. Thus, the coadministration of lower doses of a NSAID or a selective COX-2 inhibitor
plus minocycline could be useful in the management of inflammatory pain and arthritis.
Background
Minocycline, a second-generation semisynthetic tetracy-
cline antibiotic, has pleiotropic biologic activities besides
its antimicrobial activities. Apart from its use as an
antibiotic it is used in the management of various
inflammatory diseases such as rheumatoid arthritis, peri-
odontitis and several dermatological conditions [1]. In
the management of rheumatoid arthritis minocycline is
used as a disease-modifying antirheumatic drug
(DMARD) and it alleviates joint tenderness and swelling
among other features of the disease [2-5].
Recently, interest has arisen on its possible use in the
management of pain. Research has been mostly on neu-
ropathic pain where it has been shown that preemptive
treatment with minocycline has protective effects but is
ineffective once pain has developed [6,7]. It has also
been reported to have antinociceptive effects in various
models of inflammatory pain such as the formalin-
induced nociception test and its antinociceptive effects
have been suggested to be more of an anti-inflammatory
nature rather than a centrally acting analgesic [8].
In this study the antinociceptive effects of co-adminis-
tration of minocycline with a non-steroidal anti-
inflammatory drug (NSAID), indomethacin, a selective
inhibitor of COX-1, FR122047 or a selective COX-2
inhibitor, CAY10404, were evaluated in naïve mice and
mice with lipopolysaccharide (LPS)-induced thermal
hyperalgesia and monoarthritis. LPS is an endotoxin
from gram-negative bacterial cell wall, which when
administered intra-articularly into the ankle joint of a
rodent limb can induce arthritis [9,10]. When the endo-
toxin is administered intraperitoneally it can cause gen-
eralized hyperalgesia. Various mechanisms are
purported to be responsible for the LPS-induced hyper-
algesia including the release and activation of pro-
inflammatory cytokines and gelatinases, as well as glial
cell activation [11-15]. Cytokines such as TNF-a and IL-
1b cause the release of nociceptive mediators such as
prostaglandins and sympathetic amines which lower the
nociceptive threshold of sensory nerves [16-19]. Indo-
methacin is used in the treatment of various inflamma-
tory diseases such as rheumatoid arthritis, osteoarthritis,
gout, and ankylosing spondylitis [20-23]. NSAIDs are a
heterogenous group of drugs commonly used in the
management of inflammatory pain [24-27]. They pro-
duce their basic analgesic effect via inhibition of
cyclooxygenase (COX) enzymes [25-27]. The analgesic
effects of NSAIDs are also due to a number of mechan-
isms including a central mechanism involving both
prostaglandin synthesis inhibition and probably changes
in the endocannabinoid and monoaminergic system
[28-32].
Methods
Animals
BALB/c (n = 338) and C57BL/6 (n = 32) mice (8 to 12
weeks old; 20 - 30 g) were used and were supplied by
the breeding unit at the Health Sciences Center, Kuwait
University, Kuwait, and were kept in temperature con-
trolled (24 ± 1°C) rooms with food and water ad libi-
tum. All experiments were performed during the same
period of the day (8:00 AM to 4:00 PM) to exclude diur-
nal variations in pharmacological effects. The animals
were handled in compliance with European Commu-
nities Council Directive 86/609 for the care of labora-
tory animals and ethical guidelines for research in
experimental pain with conscious animals [33]. All pro-
cedures were approved by the Kuwait University Health
Sciences Center animal care committee.
Drug treatment and assessment of thermal nociception
Minocycline and indomethacin (up to 10 mg/kg) (Sigma-
Aldrich, St Louis, MO, USA) were dissolved in phosphate
buffered saline (PBS). Indomethacin (≥ 20 mg/kg) (Sigma-
Aldrich, USA)), selective COX-1 inhibitor, FR122047
[34,35] and selective COX-2 inhibitor, CAY10404 [36]
(both from Cayman Chemical, Ann Arbor, MI, USA) were
dissolved in peanut oil (Sigma-Aldrich, USA).
BALB/c or C57BL/6 mice were treated intraperitone-
ally (i.p.) with minocycline, indomethacin, FR122047,
CAY10404 or their vehicles at a volume of 5 μl/g body
mass. For the evaluation of coadministration, mice
received two separate i.p. injections at the same time:
minocycline + indomethacin, minocycline + FR122047,
minocycline + CAY10404, minocycline + vehicle for
indomethacin, minocycline + vehicle for FR122047, min-
ocycline + vehicle for CAY10404, indomethacin + vehi-
cle for minocycline, FR122047 + vehicle for minocycline
or CAY10404 + vehicle for minocycline.
Thermal hyperalgesia was induced by administering
LPS (Sigma-Aldrich, St Louis, MO, USA) at 1 mg/kg at
av o l u m eo f5μl/g body mass. Reaction latency to the
hot plate were measured before LPS administration and
over a period of 1 month after LPS administration. Mice
were treated intraperitoneally with drugs on the seventh
day after LPS inoculation based on thermal hyperalgesia
results (see Results section) and the effects of drug treat-
ment on LPS-induced thermal hyperalgesia evaluated.
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before (baseline latency) and at various times starting at
30 minutes after drug treatment. Briefly, mice were indi-
vidually placed on a hot plate (Panlab SL, Barcelona,
Spain) with the temperature adjusted to 55 ± 1 °C. The
time to the first sign of nociception, paw licking, flinch-
ing or jump response to avoid the heat was recorded
and the animal immediately removed from the hot
plate. A cut-off period of 20 seconds was maintained to
avoid damage to the paws.
Induction of monoarthritis and evaluation of changes in
weight bearing and paw print area
Inflammatory monoarthritis was induced as described
previously [9,10]. Briefly, mice were anaesthetized with
halothane and LPS 10 μgi n2 0μl PBS was injected
intra-articularly into the right hind limb ankle joint
through the Achilles tendon using a 30½-gauge needle.
PBS (20 μl) was administered in the same way to the
control group. The mice were made to cross the Cat-
walk walkway before LPS-inoculation and at 2 days
post-LPS inoculation as described previously [10].
Mice were treated intraperitoneally with indomethacin
1 and 10 mg/kg, minocycline (50 mg/kg) alone, both
drugs at the same time or their vehicles on the second
day after LPS inoculation based on the weight bearing
results [10]. The mice were then made to cross the Cat-
walk walkway at 1 hour post-drug treatment.
Paw pressure intensity and print areas of freely mov-
ing animals were measured using the Catwalk gait ana-
lysis system (Noldus Information Technology, The
Netherlands) as described previously [10,37]. Briefly, the
CatWalk instrument consists of an enclosed walkway
with a glass plate, a high speed colour camera, and a
recording and analysis software to assess the locomotor
performance of rodent models. Each mouse was placed
individually in the CatWalk walkway and allowed to
walk freely and traverse from one side to the other of
the walkway glass plate. The recordings were carried out
when the room was completely dark, except for the light
from the computer screen. Light from a fluorescent
lamp was emitted inside the glass plate and completely
internally reflected. Where the mouse paws made con-
tact with the glass plate, light was reflected down and
the illuminated contact areas recorded with a high
speed colour video camera that was positioned under-
neath the glass plate connected to a computer that runs
t h eC a t W a l ks o f t w a r e7 . 1 .T h es o f t w a r ea u t o m a t i c a l l y
labelled all the areas containing pixels above the set
threshold (7 pixels). These areas were identified and
assigned to the respective paws. Analysis of the record-
ing generated a wide range of parameters of which only
paw pressure (light intensity, which is the mean bright-
ness of all pixels of the print at maximum paw contact,
ranging from 0-255 arbitrary units) and paw print area
(complete surface area contacted by the paw during a
stance phase) were analysed.
Data analysis
The results in the text and figures are expressed as the
means ± S.E.M. For the hot plate test percentage of
change from baseline latency was calculated as follows:
for naïve mice (response latency after drug treatment -
baseline latency)/baseline latency × 100 and for mice
with LPS-induced hyperalgesia (response latency after
drug treatment - latency before drug treatment at 7
days post LPS inoculation)/l a t e n c yb e f o r ed r u gt r e a t -
ment at 7 days post LPS inoculation × 100. For the Cat-
walk gait analysis weight bearing was measured as the
right hind (RH)/left hind (LH) limb ratio of the light
intensity and the print area ratio was obtained from the
RH/LH print areas. Percentage of change after drug
treatment was calculated as follows: (light intensity or
print area ratio after drug treatment - light intensity or
print area ratio before drug treatment at 2 days post
LPS inoculation)/light intensity or print area ratio before
drug treatment at 2 days post LPS inoculation × 100.
Statistical analyses were performed using two-way analy-
sis of variance (ANOVA) followed by Bonferroni post-
tests or one-way ANOVA followed by Newman-Keuls
multiple comparison test. The differences were consid-
ered significant at p < 0.05.
Results
Effect of treatment with indomethacin, minocycline or
coadministration of minocycline plus indomethacin in a
hot plate test in naïve BALB/c and C57BL/6 mice
The administration of indomethacin (5 to 50 mg/kg
intraperitoneally) to naïve BALB/c mice did not result
in a significant change in reaction latency compared to
baseline latency in the hot plate at 55°C compared to
vehicle treatment (Figure 1 and Table 1). The adminis-
tration of minocycline 50 mg/kg (this dose has been
used previously in other pain studies [6,8]) intraperito-
neally to BALB/c mice produced a time dependent
reduction in reaction latency in the hot plate at 55°C
(Figure 1). The reaction latency fell from a baseline
latency of 12.66 ± 0.42 s to 8.31 ± 0.60 s at 1 hour post
minocycline administration and by 2 hours it had
returned to baseline reaction latency. The minocycline-
induced reduction of reaction latency time from baseline
value was dose dependent (Table 1). However, the coad-
ministration of indomethacin 5 or 10 mg/kg and
minocycline 50 mg/kg resulted in an increase in the
reaction latency time compared to vehicle treated ani-
mals or indomethacin or minocycline alone (Figure 1
and Table 1). The effects of indomethacin 10 mg/kg,
minocycline 50 mg/kg or coadministration of the two
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mouse strain, C57BL/6, with similar results (Table 2). In
order to determine the role of specific COX isoenzyme
inhibition on this potentiated antinociceptive effects,
minocycline was coadministered with selective COX
inhibitors. The administration of a selective inhibitor of
COX-1, FR122047 (10 mg/kg intraperitoneally) or a
selective inhibitor of COX-2, CAY10404 (10 mg/kg
intraperitoneally) to BALB/c did not result in a signifi-
cant change in reaction latency compared to baseline
latency in the hot plate or compared to vehicle treat-
ment (Table 3). The coadministration of minocycline 50
mg/kg and FR122047 10 mg/kg did not significantly
change the reduced reaction latency caused by minocy-
cline (p > 0.05, Table 3). However, the coadministration
of minocycline 50 mg/kg and CAY10404 10 mg/kg
resulted in a significant increase in reaction latency (p <
0.01) at 1 hour post treatment compared to vehicle or
minocycline alone, respectively (Table 3).
Effect of treatment with indomethacin, minocycline or
coadministration of minocycline plus indomethacin in a
hot plate test in BALB/c mice with LPS-induced thermal
hyperalgesia
Inflammatory hyperalgesia to thermal nociception was
i n d u c e di nB A L B / cm i c eb yas i n g l ei . p .a d m i n i s t r a t i o n
Figure 1 Coadministration of minocycline with indomethacin
produces antinociceptive effects in the hot plate test. Effect of
intraperitoneal treatment with indomethacin, minocycline or a
combination of minocycline plus indomethacin in a hot plate test in
naïve BALB/c mice. Time course of the reaction latency times for
minocycline (50 mg/kg, n = 15), indomethacin (10 mg/kg, n = 16),
minocycline + indomethacin (n = 16) or their vehicles (n = 16).
Each point represents the mean ± S.E.M of the values obtained
from 15 to 16 animals. Statistically significant differences in
comparison with drug vehicle: * p < 0.05 and ** p < 0.01; and
between minocycline or indomethacin and the combination of
minocycline + indomethacin treatments:
# p < 0.05 and
##p < 0.01
(two-way ANOVA followed by Bonferroni test).
Table 1 Percentage of change from baseline reaction latency of BALB/c mice at 1 hour post-drug treatment in the hot
plate test
Drug and dose administered to
mice
% Change in reaction latency (mean ± S.E.M of the values obtained from 6 to
16 animals.)
#
Statistical
significance
§
Vehicle for indomethacin -4.64 ± 4.619 (n = 7)
Indomethacin 5 mg/kg -10.43 ± 4.11 (n = 7) ns
Indomethacin 10 mg/kg -1.02 ± 3.85 (n = 7) ns
Indomethacin 20 mg/kg -6.43 ± 5.75 (n = 7) ns
Indomethacin 50 mg/kg 2.03 ± 10.29 (n = 7) ns
Vehicle for minocycline -5.34 ± 2.68 (n = 16)
Minocycline 12.5 mg/kg -6.78 ± 3.09 (n = 11) ns
Minocycline 25 mg/kg -21.63 ± 2.24 (n = 11) **
Minocycline 50 mg/kg -34.16 ± 4.31 (n = 10) **
Minocycline 100 mg/kg -34.21 ± 4.08 (n = 8) **
Vehicles for indomethacin and
minocycline
-4.97 ± 2.51 (n = 16)
Indomethacin 5 + minocycline 50
mg/kg
21.49 ± 4.70 (n = 6) **
Indomethacin 10 + minocycline 50
mg/kg
24.567 ± 4.05 (n = 16) **
Indomethacin 10 + minocycline 25
mg/kg
-7.65 ± 4.97 (n = 6) ns
# (response latency after drug treatment - baseline latency)/baseline latency × 100.
§Statistically significant differences in comparison with drug vehicle: ** p < 0.01; ns: no statically significant differences in comparison with drug vehicle (one-way
ANOVA followed by Newman-Keuls test).
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solved in PBS. A significant reduction in response
latency time to thermal stimuli compared to the baseline
latency in the hot plate test was observed in LPS-inocu-
lated mice from 4 to 14 days post inoculation (Figure 2).
Mice with LPS-induced hyperalgesia to thermal noci-
ception at 7 days post inoculation (Figure 3A) were trea-
ted with indomethacin, minocycline or minocycline plus
indomethacin coadminstration and their reaction latency
to the hot plate recorded.
The administration of indomethacin (10 mg/kg) or
minocycline (50 mg/kg) to mice with LPS-induced ther-
mal hyperalgesia did not produce significant changes
compared to vehicle treated mice. However, both drugs
showed a tendency to have some antinociceptive activity
at 1 hour post treatment (increased percentage change
in reaction latency after treatment compared to before
treatment) in mice with LPS-induced thermal hyperalge-
sia (Figure 3B). The effects of indomethacin or minocy-
cline compared to vehicle treatment were 31.4 ± 10.9%
and 43.2 ± 16.0% increase in reaction latency time after
treatment with minocycline or indomethacin, respec-
tively, compared to 2.1 ± 7.4% after vehicle treatment.
Coadministration of minocycline 50 mg/kg plus indo-
methacin 10 mg/kg to mice with LPS-induced hyperal-
gesia resulted in antinociceptive activity (Figure 3B).
The effects of the combination treatment compared to
vehicle treatment were significant at 1 hour post treat-
ment (61.9 ± 20.3% in reaction latency time after treat-
ment with minocycline plus indomethacin compared to
2.1 ± 7.4% after vehicle treatment at 1 hour).
Effect of treatment with indomethacin, minocycline or
coadministration of minocycline plus indomethacin in
C57BL/6 mice with LPS-induced monoarthritis
Recently we reported that the Catwalk gait analysis
system can be used to objectively quantify weight bear-
ing changes and evaluate pharmacological antinocicep-
tion in freely moving mice with LPS-induced
monoarthritis [10].
Weight bearing changes were calculated using the
ratio of right hind (RH) limb to the left hind (LH) limb
paw pressure intensity (light intensity). The ratio of RH/
LH paw print area were also measured.
The RH/LH paw pressure ratio of the control group
remained constant throughout the experiment, whereas
Table 2 Percentage of change from baseline reaction latency times of C57BL/6 mice at 1 hour post-drug treatment in
the hot plate test
Drug and dose administered to
mice
% Change in reaction latency (mean ± S.E.M of the values obtained from 7 to 9
animals.)
#
Statistical
significance
§
Vehicles for indomethacin and
minocycline
-8.62 ± 5.65 (n = 7)
Indomethacin 10 mg/kg 3.25 ± 6.05 (n = 8) ns
Minocycline 50 mg/kg -34.85 ± 3.88 (n = 8) **
Indomethacin 10 + minocycline 50
mg/kg
32.74 ± 10.85 (n = 9) **
# (response latency after drug treatment - baseline latency)/baseline latency × 100.
§Statistically significant differences in comparison with drug vehicle: ** p < 0.01; ns: no statically significant differences in comparison with drug vehicle (one-way
ANOVA followed by Newman-Keuls test).
Table 3 Percentage of change from baseline reaction latency times of BALBc mice at 1 hour post-drug treatment with
minocycline plus selective COX inhibitors in the hot plate test
Drug and dose administered to
mice
% Change in reaction latency (mean ± S.E.M of the values obtained from 8 to
11 animals.)
#
Statistical
significance
§
Vehicles (for COX inhibitors and
minocycline)
-5.11 ± 4.05 (n = 10)
selective COX-1 inhibitor, FR122047 10
mg/kg
4.33 ± 6.81 (n = 11) ns
selective COX-2 inhibitor, CAY10404 10
mg/kg
12.85 ± 6.29 (n = 8) ns
Minocycline 50 mg/kg -26.34 ± 3.35 (n = 9) **
FR122047 10 + minocycline 50 mg/kg -11.68 ± 4.61 (n = 11) ns, nz
CAY10404 10 + minocycline 50 mg/kg 24.22 ± 5.81 (n = 10) **, # #
# (response latency after drug treatment - baseline latency)/baseline latency × 100.
§ Statistically significant differences in comparison with drug vehicle: ** p < 0.01; ns: no statically significant differences in comparison with drug vehicle;
statistically significant differences between minocycline alone and the combination of minocycline + selective COX inhibitor treatments:
##p < 0.01; nz: no
statically significant differences in comparison with minocycline alone (one-way ANOVA followed by Newman-Keuls test).
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LPS administration compared to baseline or control
mice (p < 0.01; Figure 4A) similar to what has been
described previously [10].
The changes observed in paw print area ratios in LPS
inoculated mice compared to solvent-injected controls
were similar to those observed in paw pressure ratios.
T h eR H / L Hp r i n ta r e ar a t i oo ft h ec o n t r o lg r o u p
remained constant throughout the experiment, whereas
those of LPS inoculated mice decreased at 2 days after
LPS administration compared to baseline or control
mice (p < 0.05; Figure 4B).
We observed that a higher dose of indomethacin
(10 mg/kg) can alleviate the weight bearing deficits in
mice with LPS-induced monoarthritis (data not shown)
as previously described [10]. Treatment of mice with
LPS-induced monoarthritis using either indomethacin 1
mg/kg or minocycline 50 mg/kg alone had no significant
effect on the weight bearing or print area ratios deficits
observed in these mice (Figure 4A,B). Mice with LPS-
induced monoarthritis which were treated with the com-
bination of minocycline 50 mg/kg plus indomethacin 1
mg/kg had less weight bearing deficits and their RH/LH
paw pressure or print area ratios reverted to be similar to
control animals, (no significant differences between con-
trol mice and those treated with the combination, Figure
4A,B). Coadministration of minocycline 50 mg/kg plus
indomethacin 1 mg/kg to mice with LPS-induced mono-
arthritis significantly increased the RH/LH paw pressure
or print area at 1 hour post treatment by 34.5 ± 12.3%
and 85.8 ± 23.8% respectively, compared to drug vehicle
treated monoarthritic animals which had -0.6 ± 10.1%
and -5.4 ± 23.7% change at 1 hour post treatment for
RH/LH paw pressure and print area respectively (Figure
4C,D). The effects of coadministration of minocycline
Figure 2 Lipopolysaccharide (LPS)-induces thermal hyperalgesia
in BALB/c mice. Time course of the reaction latency time to the hot
plate test after administration of LPS (1 mg/kg, n = 5, i.p.) or its
vehicle (n = 8). Each point represents the mean ± S.E.M of the values
obtained from 5-8 animals. Statistically significant differences in
comparison with drug vehicle at the same time point post treatment:
* p < 0.05 and ** p < 0.01 (two-way ANOVA followed by Bonferroni
test).
Figure 3 Coadministration of minocycline with indomethacin
enhances their effects and alleviates LPS-induced hyperalgesia.
Effect of treatment with indomethacin, minocycline or a
combination of minocycline plus indomethacin on LPS-induced
hyperalgesia at day 7 post lipopolysaccharide (LPS, 1 mg/kg, i.p.)
inoculation in a hot plate test in BALB/c mice. A: Hypernociceptive
effects of LPS, 1 mg/kg, i.p. in the hot plate model of inflammatory
thermal hyperalgesia in BALB/c mice at 7 days post inoculation.
Each point represents the mean ± S.E.M of the values obtained
from 6 vehicle-treated and 29 LPS-treated animals. Statistically
significant differences in comparison with vehicle inoculated mice at
the same time point post treatment: ** p < 0.01 (two-way ANOVA
followed by Bonferroni test). B: Percentage change in reaction
latency times from baseline values (taken at 7 days post LPS) at 1
hour after treatment with minocycline (50 mg/kg, n = 15),
indomethacin (10 mg/kg, n = 14), minocycline + indomethacin (n =
16) or their vehicles (n = 12) in hot plate test. Each bar represents
the mean ± S.E.M of the values obtained from 12 to 16 animals.
Statistically significant differences in comparison with drug vehicle: *
p < 0.05 (two-way ANOVA followed by Bonferroni test).
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cantly higher than either indomethacin or minocycline
treatment (Figure 4D).
Discussion
This is the first study to report enhanced antinociceptive
activity and alleviation of weight bearing deficits by
coadministering minocycline plus indomethacin, a
NSAID, against thermal and arthritic nociception in
mice.
The enhanced antinociceptive effects produced by
coadministering minocycline plus indomethacin on
inflammatory hyperalgesia and monoarthritis-induced
weight bearing deficits could be useful in the manage-
ment of inflammation and pain in patients with arthritis.
Both drugs, minocycline and indomethacin, are used in
the management of rheumatoid arthritis (RA) [1,5,21].
However, potentiation of each other’s activities by the
two compounds in alleviating pain and weight bearing
deficits caused by inflammation or arthritis have not yet
Figure 4 Coadministration of minocycline with indomethacin alleviates weight bearing deficits in mice with LPS-induced
monoarthritis. Effects of indomethacin 1 mg/kg, minocycline 50 mg/kg or a combination of minocycline 50 mg/kg plus indomethacin 1 mg/kg
on A: weight bearing (measured as ratio of light intensity between right hind (RH) and left hind (LH) limbs) and B: ratio of RH/LH print area of
mice with LPS-induced arthritis. The drugs or their vehicles were administered at 2 days post-LPS administration and their effects measured at
1 hour after drug treatment. Each point represents the mean ± S.E.M of the values obtained from 6 to 9 animals. Non-arthritic control (n = 9)
and arthritic mice (LPS-inoculated) treated with vehicle (n = 7), indomethacin 1 mg/kg (n = 7), minocycline 50 mg/kg (n = 8) or a combination
of minocycline 50 mg/kg plus indomethacin 1 mg/kg (n = 6). Statistically significant differences in comparison with non-arthritic control (vehicle
only injected) group: * p < 0.05 and ** p < 0.01 (two-way ANOVA followed by Bonferroni test). C and D: Percentage change in RH/LH light
intensity and print area ratios from LPS-induced monoarthritic mice at 1 hour after drug treatment. Each bar represents the mean ± S.E.M of the
values obtained from 6 to 8 animals. Arthritic mice (LPS-inoculated) treated with vehicle (n = 7), indomethacin 1 mg/kg (n = 7), minocycline 50
mg/kg (n = 8) or a combination of minocycline 50 mg/kg plus indomethacin 1 mg/kg (n = 6). Statistically significant differences in comparison
with drug vehicle treated group: * p < 0.05 and ** p < 0.01; and between indomethacin or minocycline alone versus minocycline plus
indomethacin combination treated mice:
# p < 0.05 and
##p < 0.01 (one-way ANOVA followed by Newman-Keuls multiple comparison test).
Abu-Ghefreh and Masocha BMC Musculoskeletal Disorders 2010, 11:276
http://www.biomedcentral.com/1471-2474/11/276
Page 7 of 10been reported. This potentiation of analgesic activity
could have been missed in human RA because the inter-
est on minocycline has been on its DMARD activity but
not analgesic effects, moreover minocycline on its own
even in our experimental setting does not have signifi-
cant analgesic activity. It would be interesting to study
in patients with arthritis whether co-administration of
minocycline and indomethacin (or other NSAIDs) pro-
duce better analgesic activity than indomethacin or
NSAIDs alone.
The LPS-induced hyperalgesia has been suggested to
be due to the release and activation of pro-inflammatory
cytokines and gelatinases, as well as glial cell activation
[11-15]. Minocycline inhibits the synthesis and activity
of gelatinases, the synthesis and release of cytokines as
well a glial activation [7,38-42]. Thus some of the
analgesic activities of minocycline observed in LPS-
induced hyperalgesia but not in naïve animals could be
due to its activities on cytokines, gelatinases and glial
cells amongst other molecules and cells which are acti-
vated and involved in pain during inflammation.
We have previously observed that higher doses of
indomethacin (10 mg/kg and above) resulted in even
load distribution between the arthritic right hind limb
and the non-arthritic left hind limb in mice with LPS-
induced arthritis similar to control animals without
monoarthritis, using the Catwalk gait analysis method
[10]. In the current study a lower dose of indomethacin
(1 mg/kg) or minocycline at 50 mg/kg alone could not
reverse the weight bearing deficits caused by monoar-
thritis, however, coadministration of minocycline
50 mg/kg with indomethacin at 1 mg/kg alleviated the
weight bearing deficits induced by monoarthritis. The
observed ability to restore weight bearing deficits has
relevance to arthritis since patients with unilateral knee
osteoarthritis transfer weight load from the arthritic leg
to the hip and knee of the uninvolved leg; and relieving
pain in the affected knee, results in even load distribu-
tion between the legs [43,44].
Minocycline has anti-inflammatory activities and is
used as a disease modifying antirheumatic drug. It has
been reported to inhibit T cell activation, gletanisases
and other matrix proteases activity and cytokine produc-
tion in rheumatoid arthritis, thus reducing inflammation
[45-48]. On the other hand indomethacin is purported
to produce analgesia and anti-inflammatory activity
through the inhibition of cycloxygenase and prostaglan-
din synthesis [21,49]. Since these drugs affect different
targets, all involved in inflammation and pain during
arthritis, coadministration could result in an enhance-
ment of each other’s activity and be more effective at
lower doses.
Other possible reasons for the enhanced antinocicep-
tive activity by coadministering minocycline and
indomethacin could have been due to the inhibition of
COX enzyme activity by indomethacin and inhibition of
5-lipoxygenase activity by minocycline. The inhibition of
COX-2 isoenzyme seems to be important for this syner-
gism since coadministration of minocycline with
CAY10404, a selective inhibitor of COX-2 [36] but not
FR122047, a selective inhibitor of COX-1 [34,35], pro-
duced antinociceptive activity. Minocycline has been
reported to block 5-lipoxygenase activation [50].
Recently, administration of a5 - l i p o x y g e n a s ei n h i b i t o r
has been reported to potentiate the antinociceptive
activity of NSAIDs [51]. Thus, the 5-lipoxygenase inhibi-
tory activity of minocycline could potentiate the activity
of the NSAID, indomethacin. The other possible reason
for the synergism on antinociception could be that the
two drugs synergistically alter the endocannabinoid sys-
tem in the central nervous system (CNS). Minocycline
and indomethacin can both independently alter endo-
cannabinoid levels or activity in the CNS and this has
been linked to their antinociceptive activity [52,53].
Endocannabinoids have anti-inflammatory activities,
antinociceptive activities and can reduce thermal hyper-
lagesia in rodents [54-56]. Possible biochemical path-
ways involved in minocycline and indomethacin
enhancement of each other’s antinociceptive activity
warrants further research.
Conclusions
Using mice models of inflammation-induced thermal
hyperalgesia and monoarthritis we show that coadminis-
tration of minocycline with indomethacin or a selective
COX-2 inhibitor, CAY10404 potentiates their effects
and results in antinociception against thermal nocicep-
tion, reduction of thermal hyperalgesia and alleviation of
weight bearing deficits in arthritic mice at doses where
either drug alone has no significant activity. Thus, the
combination of lower doses of a NSAID plus minocy-
cline could be useful in the management of inflamma-
tory pain and arthritis with less dose-dependent side
effects.
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